Showing 1-10 of 364 results for "".
- Donald A Glass II, MD, PhD, FAADhttps://practicaldermatology.com/profiles/donald-a-glass-ii-md-phd-faad/OE6nA2/
- ICYMI: Dispatches from The Skin of Color Society’s 18th Annual Scientific Symposiumhttps://practicaldermatology.com/news/icymi-dispatches-from-the-skin-of-color-societys-18th-annual-scientific-symposium/2461157/The Skin of Color Society’s 18th Annual Scientific Symposium wowed the crowd during the American Academy of Dermatology's Annual Meeting in Boston. This year's SOCS Scientific Symposium was co-chaired by Andrew Alexis, MD, MPH, FAAD, Professor of Clinical Dermatology, Vice-Chair for Diversity and…
- White (But Not Red) Wine Linked to Rosaceahttps://practicaldermatology.com/news/white-but-not-red-wine-linked-to-rosacaea/2458216/White wine and liquor may increase rosacea risk, according to a new study in the Journal of the American Academy of Dermatology. It is widely held that red wine consumption is linked to rosacea, but the new study points to other types of alcohol as the more likely culprits. The study analyzed data…
PROLITE III, IPL System by Quantel Derma
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/prolite-iii-ipl-system-by-quantel-derma/19374/PROLITE III by Quantel Derma - The Right Choice for the Right Pulse. The powerful intense pulsed light system (IPL) - high-speed treatments for photo rejuvenation and permanent hair removal. An effective contact cooling is integrated in the handpieces. A variable pulse formation makes PROLITE III ex- FDA Approves BMS’ Opdivo (Nivolumab) for Adjuvant Treatment of Eligible Patients with Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/fda-approves-bms-opdivo-nivolumab-for-adjuvant-treatment-of-eligible-patients-with-completely-resected-stage-iib-or-iic-melanoma/2462074/The U.S. Food and Drug Administration (FDA) has given its nod to Opdivo (nivolumab) for the adjuvant treatment of eligible adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma. This approval was based on the Phase 3 CheckMate -76K trial, which compare…
- European Commission Green Lights Opdivo as an Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/european-commission-green-lights-opdivo-as-an-adjuvant-treatment-for-completely-resected-stage-iib-or-iic-melanoma/2461960/The European Commission (EC) has approved Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of adults and adolescents 12 years of age and older with stage IIB or IIC melanoma who have undergone complete resection, Bristol Myers Squibb reports. The EC approval covers all European Union…
- Positive Topline Data Seen in Phase II Trial of LNK01001 in ADhttps://practicaldermatology.com/news/positive-topline-data-seen-in-phase-ii-trial-of-lnk01001-in-ad/2461916/Lynk Pharmaceuticals Co., Ltd.’s LNK01001 performed well in a Phase II clinical trial for the treatment of atopic dermatitis (AD), according to positive topline data from the Company. LNK01001 is a highly selective JAK1 inhibitor that blocks JAK1 without crossing over onto other JAK subtypes. The…
- Vial, Nielsen BioSciences Partner in Phase III Clinical Trial of Candin for Common Wartshttps://practicaldermatology.com/news/vial-nielsen-biosciences-partner-in-phase-iii-clinical-trial-of-candin-for-common-warts/2461783/Vial is partnering with Nielsen BioSciences, Inc. to study the safety and efficacy of Candin for the treatment of common warts. Vial will support Nielsen with their Phase III, randomized, double-blind, placebo-controlled clinical study of Candin for the treatment of Verruca vulgaris in adolescent…
- First Patient Dosed in Phase II Clinical Trial of TLL018-205 for PsOhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-ii-clinical-trial-of-tll018-205-for-pso/2461511/The first patient has been enrolled and dosed in a Phase II study evaluating the efficacy and safety of TLL-018 fpr moderate to severe plaque psoriasis. This study is sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd (Highlightll Pharmaceutical, USA). TLL-018 is a novel, highly potent, a…
- Reistone Biopharma's Oral Ivarmacitinib Meets Primary Endpoint in Phase III Study for ADhttps://practicaldermatology.com/news/reistone-biopharmas-oral-ivarmacitinib-meets-primary-endpoint-in-phase-iii-study-for-ad/2461431/Reistone Biopharma’s once daily Ivarmacitinib as monotherapy relieves in improving skin inflammation and itchiness n adults and adolescents with moderate-to-severe, according to a results from thePhase III QUARTZ3 study. The study evaluated the efficacy and safety of once daily Ivarmacitinib as mo…
- Prev
- Next